SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Relapsed or Refractory Multiple Myeloma
Related studies linked through entity extraction aliases.
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE1
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
- Status
- COMPLETED
- Phase
- PHASE2
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE1
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE1
A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
- Status
- TERMINATED
- Phase
- PHASE2
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE1
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)
- Status
- COMPLETED
- Phase
- PHASE2
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide
- Status
- COMPLETED
- Phase
- PHASE2
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
- Status
- COMPLETED
- Phase
- PHASE2